Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De Lleida

At Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De Lleida, clinical research in cardiovascular diseases focuses on preventing major events, protecting heart function, and improving outcomes after stroke or heart attack. The studies include patients with acute coronary syndrome, cardiovascular disease, and people with inherited risk for dilated cardiomyopathy.

• Testing new ways to reduce the risk of heart attack, stroke, and other serious cardiovascular complications
• Evaluating early treatment strategies for people carrying genetic variants linked to heart muscle disease
• Studying therapies for stroke prevention after acute ischemic events or high-risk transient ischemic attack

This research reflects a strong interest in both prevention and long-term protection of the heart and blood vessels.

A major part of the site’s trial portfolio is dedicated to neoplasms, especially breast cancer, lung cancer, and ovarian cancer. Research here also includes advanced disease settings, recurrence prevention, and treatment options for tumors with specific molecular features.

• Evaluating new treatment approaches for early, advanced, and metastatic breast cancer
• Studying therapies for non-small cell lung cancer and other solid tumors with HER2-related alterations
• Assessing strategies for ovarian and colorectal cancers with targeted biological characteristics

The oncology program at this hospital is centered on improving cancer control, delaying recurrence, and matching treatment to tumor biology.

The site contributes to research in nervous system diseases, with a clear emphasis on acute ischemic stroke, transient ischemic attack, and multiple sclerosis. These studies are aimed at reducing neurological damage and improving safety and recovery over time.

• Testing medicines intended to prevent recurrent stroke after a recent ischemic event
• Assessing longer-term safety and tolerability in relapsing and progressive multiple sclerosis
• Exploring treatments for pain-related complications after surgery that affect quality of life

This field combines prevention, symptom control, and broader neurological care.

Clinical trials at the site also address nutritional and metabolic diseases, immune system diseases, and kidney-related conditions. Key areas include obesity, type 2 diabetes mellitus, non-alcoholic steatohepatitis, IgA nephropathy, and lupus nephritis.

• Testing therapies for weight-related disease and metabolic risk reduction
• Evaluating treatments for inflammatory kidney disorders and protein loss in the urine
• Studying approaches for liver disease linked to obesity and insulin resistance

These studies aim to slow disease progression, improve organ function, and support better long-term management of chronic conditions.

The research portfolio includes acute myeloid leukemia, myelodysplastic syndrome, and related high-risk blood disorders. Work in this area focuses on improving treatment effectiveness and extending disease control for patients with aggressive hematologic cancers.

• Assessing new treatment combinations for newly diagnosed leukemia and myelodysplastic syndromes
• Studying strategies designed to improve event-free survival in high-risk blood cancers
• Exploring therapies for patients with specific genetic mutations that influence treatment response

This research supports more precise and potentially more effective care for complex blood malignancies.

The site also participates in studies across digestive system diseases, hormonal diseases, and broader clinical research topics. These include conditions such as non-alcoholic steatohepatitis, diabetes-related issues, and other chronic disorders that affect day-to-day health.

• Investigating treatments that may improve liver, metabolic, and endocrine health
• Evaluating participant-centered trial models that may improve access, retention, and satisfaction
• Supporting research that looks at safety, tolerability, and real-world usefulness of new therapies

This broader research activity shows an interest in both disease-specific treatment and better ways to deliver clinical trials at a Spain-based healthcare center.